Researches say gene therapy trials for heart disease show promising results, despite FDA "caution"
This article was originally published in Clinica
Preliminary evidence from trials of gene therapy for coronary heart disease shows that the technique is safe and could be efficacious, said angiogenesis pioneer Jeffrey Isner at the American College of Cardiology meeting in Anaheim, California, last week.
You may also be interested in...
AMAG outlines plans for retrospective real-world evidence studies, and possibly a new placebo-controlled trial with a primary endpoint of preterm birth <32 weeks, in a filing opposing the Center for Drug Evaluation and Research’s proposal to withdraw the drug.
The leading Korean pharma firm’s oral, third-generation EGFR-TKI is approved in the country, providing a new option for patients with advanced NSCLC and increasing hopes for global approvals given an ongoing global Phase III combination trial led by partner J&J.
DePuy Synthes expects its Velys robotic-assisted system to be cost-effective, easy-to-use and to be well-suited for use in ambulatory surgery centers.